Adel H. Karara, PhD, FCP

Institution:
University of Maryland Eastern Shore
Department:
School of Pharmacy
Position(s):
Professor
Current SEPA Project

Dr. Karara, is Professor of Pharmaceutical Sciences, teaches in the areas of pharmaceutics, biopharmaceutics and pharmacokinetics. Prior to joining UMES, he held senior positions in the pharmaceutical industry. His research had been primarily in the female health care area working on the pharmacokinetics/dynamics of combination hormone treatments. As Senior Clinical Pharmacologist at Roche, he had the responsibility for guiding the selection of early drug discovery compounds, due diligence projects and design of clinical pharmacology development programs for several metabolic drug candidates. Before joining Roche, he was Director at Berlex where he provided NDA support for Yasmin®, ClimaraPro® Menostar® and Angeliq®. At Novartis, he provided support for Starlix®, Lescol® and Neoral®. Dr. Karara was a tenured faculty at University of Louisiana where he mentored 3 PhD & 2 MS students and won the researcher of the year award. Dr. Karara is a Charter member of American Association of Pharmaceutical Scientists (AAPS), participated in teaching short courses and served on abstract screening committees. Dr. Karara was elected to serve as the Chair of the Clinical Pharmacology and Translational Medicine Section of AAPS. Dr. Karara has been appointed to the National Academies of Science, Engineering and Medicine’s committee on the clinical utility of treating patients with compounded bioidentical hormone replacement therapy. He has served as an invited speaker at several clinical pharmacology forums. He served on Pharmaceutical Research and Manufacturers of America, Clinical Pharmacology Technical Group where he led the exploratory Investigational New Drug (IND) survey initiative. Dr. Karara currently serves on the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee for oncology drugs (ODAC). Dr. Karara is a fellow of American College of Clinical Pharmacology and serves on the editorial board of the Journal of Clinical Pharmacology.